







Ayala Corporation filed a disclosure with the Philippine Stock Exchange on September 1, 2025. It was not a ribbon-cutting ceremony. It was a subscription agreement. ABC Impact Fund II LP, backed by Temasek Trust in Singapore, took 121,089,059 common shares. They also took 208,275,585 redeemable preferred shares. The price was P4.3013 per common share. The preferred price was P4.1972. This first tranche brought in roughly P1.4 billion. It secured an economic stake of about 16 percent in Ayala Healthcare Holdings. The unit is listed. It is the conglomerate’s hospital and drugstore arm. The filing carried a specific promise. By 2027, the company called AC Health would run at least 10 hospitals. It would manage 300 clinics. It would operate 1,150 pharmacies. The company repeats these three numbers. They form a drumbeat in their own materials. They never say it out loud. The third number is the actual business. The first two are just the front door.
AC Health turned ten in 2025. Its anniversary materials list the footprint precisely. The Healthway Medical Network holds 236 corporate and multispecialty clinics. It also holds 6 hospitals. The Generika Drugstore and St. Joseph Drug chains have 880 pharmacies. Two drug importers, IE Medica and MedEthix, hold 1,178 product registration certificates. Revenue in 2024 was P9.4 billion. It was up 10 percent from the year before. The provider side grew 22 percent in revenue in 2024. The hospital industry average was only 8 percent. The pharma side outperformed an industry that shrank 5 percent that year. A table from the filing shows the targets against mid-2025 actuals. Hospitals must grow from 6 to 10. That is a 67 percent increase. Clinics must grow from 236 to 300. That is a 27 percent increase. Pharmacies must grow from 880 to 1,150. That is a 31 percent increase. None of those rates is exotic on its own. The shape is the odd thing. The company’s filing discipline shows it knows the shape matters.
Divide the 2027 pharmacy target by the hospital target. You get 115. Do the same to the current footprint. You get about 147. A network that describes itself as an integrated healthcare ecosystem carries more than a hundred retail drugstores for every hospital it runs. If the pharmacies existed to feed the hospitals, one or two dozen would do. At this density, the arrow points the other way. The hospitals are the brand that makes the drugstore chain credible. The company’s stated expansion method confirms this reading. ABC Impact’s capital is earmarked for growth through organic initiatives and targeted acquisitions. It spans all three pillars. Hospitals are the slowest item on that list. They are the most capital-hungry. A 200-bed acute care hospital takes years of construction. Or it requires a delicate negotiation with a founding family. A pharmacy is a lease and a license. When a 2027 deadline looms, you know which of the two can be added in bulk.
The structural reason a Philippine healthcare group looks like this lives in the payer mix. It does not live in management preference. Out-of-pocket spending accounted for 41.2 percent of total health expenditures in 2025. This is based on Philippine Statistics Authority data cited during congressional budget debates. The state insurer, PhilHealth, covers 10.6 percent of total health expenditure. Its own leadership told a Senate hearing in February 2025 that it wants that share at 18.5 percent within a few years. Everything else flows through household wallets. And household wallets buy medicine first. A hospital admission is a catastrophe you finance or defer. A box of generic antihypertensives is twelve pesos you pay today. Two things changed in the payer system in 2025. Both matter to AC Health’s plan. PhilHealth raised case rates by 50 percent across around 9,000 benefit packages effective January 1, 2025. It was funded from a P284 billion corporate operating budget. P271 billion of that goes to benefit payments. The same budget funds priority packages. They read like a list of the most expensive things a Filipino household can face. KonSulTa primary care pays P1,700 to P2,100 per person. It covers 156 hemodialysis sessions at P6,350 per session. It adds new outpatient coverage for emergency care and mental health. The same budget year carried zero government premium subsidy for indirect contributors. The expansion had to be self-funded. Benefit payouts have surged accordingly. They hit P83 billion in 2023. They reached P330 billion in 2025. The stated target for 2026 is P420 billion. If that trajectory holds, the pressure on household wallets eases at the margin. Formal care gets a little less deferrable.
The gaps the state leaves open are easiest to see at the counter. PhilHealth’s dental benefit shoulders P1,000 per year. It covers assessment and cleaning across two visits at accredited government clinics. Private dental providers typically charge P1,500 to P1,600 per visit. A benefit that covers less than one private appointment per year is not coverage in any meaningful sense. It is a voucher. Multiply that arithmetic across dermatology, consultations, and maintenance medicine. You have the customer base Generika was built for. These are people who are insured on paper and self-pay in practice. The pharmacy chain does not compete with PhilHealth. It harvests what PhilHealth does not reach. Now run the arithmetic yourself. If PhilHealth succeeds in cutting out-of-pocket spending to its stated 25 to 30 percent goal, more drug purchases shift to prescriptions attached to formal care. Pharmacy footfall follows prescriptions rather than impulse. That helps a chain with an integrated distributor. If PhilHealth stalls, the current model works exactly as built. Patients keep paying cash at the counter. The pharmacy-heavy shape wins in both branches. That is not a criticism of the strategy. It is the reason the strategy is what it is. A network built this way does not bet on a single policy outcome. It bets on the wallet. And the wallet is always there, whether the state pays or the family pays.